New HPLC Quadruples Clinical Throughput Capabilities, Displayed at AACC 2015

Thermo Fisher Scientific Inc. (Waltham, MA, USA) now offers its new Prelude LX-4 MD HPLC, listed with the FDA as a Class I medical device for general clinical use. Prelude LX-4 MD HPLC quadruples the productivity of a single-channel HPLC by using four parallel channels to deliver up to 4 separations in a single instrument, streamlining LC-MS workflows, reducing mass spectrometer idle time, and keeping free valuable bench space. The four channels can run identical or different LC-MS assays simultaneously, providing flexibility for varying clinical separations and maximizing mass spectrometer utilization.

"We are strongly committed to bringing the advantages of LC-MS to the clinical market,” said Bradley Hart, Thermo Fisher Scientific, “The Prelude LX-4 MD is one of the first products within a broader initiative to make sample separations and mass spectrometry more useful and accessible to the clinician.”

Prelude LX-4 MD is the newest addition to the family of Thermo Scientific chromatography and mass spectrometry instruments and software for the clinical lab, which includes the Endura MD triple quadrupole mass spectrometer, Prelude MD HPLC, and software ClinQuan MD.

Related Links:
Thermo Fisher Scientific
Thermo Scientific Clinical Diagnostics
American Association for Clinical Chemistry (AACC)